News Jimenez to step down as Novartis chief, Narasimhan takes ove... Joe Jimenez is to step down after eight years as Novartis chief executive, and will be leaving on a high after last week’s first-in-class CAR-T approval.
News Oxford BioMedica could get $100m following CAR-T approval UK biotech will supply key component of Novartis' newly approved cancer cell therapy
Events Partner Content CRISPR & Precision Gene Editing Congress - Berlin 2017 CRISPR & Precision Gene Editing Congress Berlin 2017
News Novartis and FDA hail 'historic' Kymriah, first ever approve... In the end, the FDA took little more than six weeks to give final approval to Kymriah, the first ever CAR-T treatment.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.